In short
Clinical trials are investigating AMG 732 in healthy subjects and in people with thyroid eye disease. These studies aim to assess how well the treatment works and to gather safety and other research data. The main focus is on a Phase 1/2 study in an adult population with thyroid eye disease.
Key points
- Clinical trials of AMG 732 are being carried out in healthy subjects and in people with thyroid eye disease. The main study listed is a Phase 1/2 interventional trial with 40 planned participants. Researchers are looking at AMG 732 after multiple subcutaneous doses. The main outcome is the change in proptosis, which means how far the eye bulges forward, measured with an exophthalmometer. This trial is focused on early research to see whether AMG 732 may help in thyroid eye disease.
Trial overview
The listed study is an interventional study, which means researchers give a study treatment and then measure the results. It is testing AMG 732 in both healthy subjects and people with thyroid eye disease.
The trial title says it is a Phase 1/2 study, so it is part of early clinical research. The brief summary says the study is designed to investigate the efficacy of AMG 732 in subjects with TED after multiple subcutaneous doses.
Who is being studied
The study includes healthy subjects and subjects with thyroid eye disease. Healthy subjects are included so researchers can compare results with people who have the disease.
Thyroid eye disease, also called TED, is the main condition being studied in this trial. The source data do not list more detailed entry rules, so the full participation criteria are not available here.
Study design and phase
This study is in Phase 1/2, which usually means the research is still early and is looking at both safety and possible benefit. The study type is listed as interventional, and the treatment is given by subcutaneous use, which means under the skin.
The intervention list also includes a placebo for AMG 732, described as site-sourced normal saline in sterile single-use vials or ampoules. A placebo is a comparison treatment that does not contain the active study drug.
What the study is measuring
The main outcome is the change from baseline at week 9999 in proptosis measurement in the study eye. Proptosis means how far the eye sticks out, and this is measured with an exophthalmometer, a tool used for this purpose.
Baseline means the starting measurement before treatment begins. By comparing later measurements with the starting point, researchers can see whether the eye bulging changes over time.
Trial status and size
The trial status is listed as Authorised, which means the study has been approved to move forward. The planned enrollment is 40 people, so this is a small early-stage study.
Because the enrollment is limited, the study is likely meant to give an early look at how AMG 732 performs in this patient group. The source data do not provide final results, so the article focuses on the study design and planned measurements rather than outcomes.
What these trial terms mean for patients
If you read this study information, the most important point is that AMG 732 is being tested in people with thyroid eye disease and in healthy subjects. The researchers are looking at whether the treatment changes eye bulging, which is one of the key signs of TED.
The trial uses a placebo comparison, so some participants may receive a look-alike treatment instead of AMG 732. This helps researchers make a fair comparison when they study the results.
In simple terms, this is an early study to learn more about AMG 732 in TED, using careful measurements of the eye and comparing changes over time.